Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26857017 | 0.92 | MAPK1 (0.46) | MMP12PIK3CGPIK3CDROCK2ROCK1 | |
| SCHEMBL26857000 | 0.89 | MAPK1 (0.46) | MMP12MAPK1MET | |
| SCHEMBL26856882 | 0.88 | MMP12 (0.53) | MMP12PIK3CGPIK3CDROCK2ROCK1 | |
| SCHEMBL26857050 | 0.86 | MMP12 (0.47) | MMP12PIK3CGPIK3CDMAPK1PIK3CA | |
| SCHEMBL26857153 | 0.86 | MMP12 (0.42) | MMP12PIK3CGPIK3CDMAPK1PIK3CA | |
| SCHEMBL26857078 | 0.86 | ROCK1 (0.42) | MMP12PIK3CGPIK3CDROCK1MAPK1 | |
| SCHEMBL26857043 | 0.86 | ADORA2A (0.40) | MMP12PIK3CGPIK3CDMAPK1PIK3CA | |
| SCHEMBL26857165 | 0.85 | MMP12 (0.41) | MMP12PIK3CGPIK3CDMAPK1PIK3CA | |
| SCHEMBL26856987 | 0.84 | PIK3CG (0.46) | MMP12PIK3CGPIK3CDROCK2ROCK1 | |
| SCHEMBL26857148 | 0.84 | MARK3 (0.46) | MMP12PIK3CGPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PARK7 | MMP12 4866/4885PIK3CG 690/4885PIK3CD 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.